Delivery Order SPE2DB20D3103-SPE2DB24FL6S8
Award Date 11/27/23
Potential Completion Date 11/28/23
Potential Value $4.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,345.79 firm fixed-price delivery order contract, with a completion date of January 8, 2025, is for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the...
- This federal contract award, valued at $1,557.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S pharmaceutical products. The contract, which runs until January 8, 2025, is a firm fixed price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,107.65 firm fixed price delivery order contract is for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a specialty pharmaceutical product. This contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $7,002.97, is a delivery order with a firm fixed price. It covers the provision of MYFEMBREE 40 MG-1 MG-0.5 MG tablets, with an ultimate completion date of November 8, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,345.59, is for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG tablets. It is a firm fixed-price delivery order contract that runs through April 1, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,491.58 firm fixed-price delivery order is for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a medication. The contract has a completion date of February 26, 2024 and was awarded on February 23, 2024. The award is not designated as a set-aside contract. AmerisourceBergen holds a significant $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, awarded on October 30, 2024, is a Firm Fixed Price Delivery Order valued at $1,180.74 with a completion date of October 31, 2024. The contract covers the procurement of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product, with no set-aside designation. AmerisourceBergen also holds a significant...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,167.58, is a Firm Fixed Price Delivery Order for the supply of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, a pharmaceutical product. This award is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $2,521.79, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the product "MYFEMBREE 40/1/0.5 28S" with a completion date of December 18, 2024. The contract type is Firm Fixed Price. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,530.90 firm fixed-price delivery order is for the medical product MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S, with a final completion date of November 6, 2023. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FL6S8Delivery Order
This federal contract award, valued at $4,466.85, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S medical products. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated with any set-aside requirements, indicating open competition.
Generated 5/12/25, 10:39 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 11/27/23 |